CARDIOFLOW-B released its interim results, with a loss attributable to shareholders of RMB 2.163 million, a year-on-year decrease of 96.17%
I'm PortAI, I can summarize articles.
CARDIOFLOW-B released its interim results for the period ending June 30, 2025, with revenue of 229 million yuan, an increase of 2.67% year-on-year. The loss attributable to shareholders was 2.163 million yuan, a decrease of 96.17% year-on-year, with a basic loss per share of 0.09 yuan. The revenue growth was mainly driven by the global commercialization of the VitaFlow Liberty® transcatheter aortic valve and its retrievable delivery system, as well as the steady progress of the AnchorMan® left atrial appendage occlusion system and guiding system in both domestic and international markets
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments